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Conclusion: DDVF do not describe adequately the delivered 
dose in the patient. Difference between planned and 
delivered doses in PTVs is reasonable, conversely anatomical 
variations seems to be a cause of overdosage in PG. Re-
planning on 18Th MVCT could brought significant benefits, in 
terms average dose of PG. 
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Purpose or Objective: Several adaptive strategies have been 
implemented to account for anatomical changes during 
radiotherapy for bladder cancer. To obtain target structures, 
either the first four CBCT scans can be used (CBCT-based 
strategy), or the interpolation of bladder volumes on 
pretreatment CT scans (CT-based strategy). The purpose of 
this study was to determine whether the CBCT-based or CT-
based strategy is more favorable in terms of tumor control 
probability (TCP) and normal tissue sparing. 
 
Material and Methods: Ten patients from each of the two 
participating institutes were analyzed, adopting the clinically 
used adaptive strategy and dose prescription from each 
institute. With the CBCT-based strategy, a library of three 
plans was created, corresponding to a small, medium and 
large bladder. Patients received 70 Gy to the bladder tumor, 
60 Gy to the non-involved bladder and 48 Gy to the lymph 
nodes, in 30-35 fractions. With the CT-based strategy, a 
library of five plans was created using two pre-treatment CT 
scans, with full and empty bladder, respectively. Patients 
received 55 Gy to the tumor and 40 Gy to bladder and lymph 
nodes, in 20 fractions.  
Tumor control: TCP was calculated for the combined target 
volumes of tumor and bladder, using the Linear-Quadratic 
model with an α/β ratio of 13 Gy. Since tumor cell density in 
the non-involved bladder wall was unknown, it was varied 
between 10^2 and 10^7 cells/cm³. To investigate the effect 
of the different dose prescriptions, the TCP was recalculated 
for the CT-based strategy with the dose scaled to 70 Gy in 35 
fractions.  
Normal tissue sparing: for rectum and bowel cavity, the 
equivalent dose in 2 Gy fractions (EQD2) was calculated using 
α/β values of 5 and 8 Gy, respectively, and DVH parameters 
were extracted. In addition, the planning target volume for 
each chosen plan divided by the daily bladder volume was 
calculated. Differences in parameters between groups were 
assessed using a Wilcoxon signed-rank test.  
 
Results: A higher TCP for the CBCT-based strategy compared 
to the CT-based strategy was found, independent of modeled 
cell density in the non-involved bladder wall (Figure 1). For a 
low cell density, median TCP for the CBCT-based strategy 
was 75%, compared to 49% for the CT-based strategy. These 
results were comparable to 3-year local control rates 
previously reported. In addition, scaling the dose from the 
CT-based strategy to 70 Gy increased the median TCP to 72%. 
For the CT-based strategy, a lower median rectum V30Gy and 
lower median bowel V45Gy compared to the CBCT-based 
strategy were observed (Figure 1). This difference is 
reflected in the finding that the PTV is on average 3.9 times 
larger than the daily bladder volume for the CBCT-strategy, 
compared to 2.2 times for the CT-based strategy (p<0.01). 
 
 
 
Conclusion: Total bladder TCP is higher for the CBCT-based 
strategy, which is due to prescription differences. The 
adaptive strategy based on CT scans results in the lowest 
rectum V30Gy (EQD2) and bowel cavity V45Gy (EQD2). 
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Purpose or Objective: To investigate the patient's movement 
during the preparation of an adaptive cranial radiosurgery 
(SRS) procedure and its dosimetric impact. 
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Material and Methods: Cranial radiosurgical treatments are 
planned in our department using IMRT technique. A Varian 
Clinac 2100 CD equipped with the OBI system and the Eclipse 
TPS are used. Patients are immobilized using the BrainLAB 
mask system. A CBCT scan is acquired after the initial laser-
based patient setup (CBCTsetup). In order to take into 
account the roll and tilt patient´s rotation errors, not 
supported by the linac couch, an online adaptive replanning 
procedure was designed (Med Dosim. 2013 Autumn;38(3):291-
7). It consists of a 6D registration-based mapping of the 
reference plan onto actual CBCTsetup, followed by a 
reoptimization of the beam fluences ("6D plan", computed on 
the CBCTsetup) to achieve similar dosage as originally was 
intended, while the patient is lying in the linac couch. Once 
the 6D plan is computed, it is activated in the record and 
verify network and the actual patient's position is again 
verified by CBCT imaging (CBCTtx): CBCTsetup/CBCTtx 4D 
match is performed on the OBI workstation.  
Twelve online procedures with detected roll or tilt rotation 
errors larger than 0.5º were enrolled in this study. 
Intrafractional patient's shifts during the time lag between 
CBCTsetup and CBCTtx was investigated, as well as the 
capability of the online adaptive method to compensate 
them. The plan 6D plan was recalculated on the CBCTtx ("6D 
plan Tx") taking into account the actual treatment isocenter 
position. Both plans (6D plan vs. 6D plan Tx) were compared 
using DVHs.  
 
Results: 
1) The magnitudes of the intrafraction shifts were 0.4 mm 
(SD: 0.7 mm), 0.6 mm (SD: 0.5 mm) and 0.3 mm (SD: 0.4 mm) 
in lateral, anterior-posterior and superior-inferior directions, 
respectively. The intrafractional rotational shifts were 0.1º 
(SD: 0.1º), 0.0º (SD: 0.1º) and 0.1º (SD: 0.2º) in tilt, yaw and 
roll directions, respectively. The time lag where these shifts 
were happen was 16 ± 2 minutes.  
2) Dose differences < 1% were found for targets and organ-at-
risks between each 6D Plan (computed on the CBCTsetup) 
and its respective 6D Plan Tx (computed on the CBCTtx). 
 
Conclusion: 
1) Patient's rotational errors during online replanning were 
negligible.  
2) Patient's translational errors during online replanning were 
compensated enough after CBCTsetup/CBCTtx 4D alignment 
performed on the OBI workstation, with no appreciable 
dosimetric impact. 
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Purpose or Objective: To investigate the impact of inter-
fraction anatomical variations in pancreatic and pelvic tumor 
patients when using carbon ion therapy through a 
retrospective adaptive approach. 
 
Material and Methods: We collected daily MVCT scans for 10 
selected patients, previously treated with helical 
tomotherapy for tumors located in the abdomen and pelvic 
region. On the first MVCT, taken as a reference, a dummy 
target volume was contoured, based on clinical experience, 
and organs at risk (OAR) original contours were imported 
from the planning CT scan and modified according to 
anatomical variations. The Hounsfield Unit (HU) to water 
equivalent path length (WEPL) calibration curve was 
experimentally determined and implemented in our TPS. 
According to prescription dose and OARs dose limits of 
clinical protocols approved at CNAO, a plan was then 
optimized on the first MVCT. For each patient, a number of 
MVCTs equal to the treatment sessions planned according to 
our fractionation scheme were fused on the reference one 
and structures were registered and manually corrected. The 
reference plan was recalculated on each MVCT scan to 
simulate a real treatment fraction. The cumulative dose was 
calculated by adding the contribution of each different 
fraction and then registered on the reference MVCT. This 
dose distribution was compared against the reference one in 
terms of target dose coverage and dose to OARs. 
 
Results: For the pelvis cases, results show no significant 
change in the target coverage, with an average PTV D95% 
decrease of 1% and a maximum daily variation of -6%, while 
the mean homogeneity index (HI) difference is less than 0.01. 
For the abdominal area, however, a clinically relevant loss in 
target coverage is found: PTV D95% decreases, on average, of 
7%, with a maximum daily variation of -23%. Target dose 
becomes less homogeneous, as shown by an average increase 
in the PTV HI of 0.08. For both districts, no clinically 
significant difference is found in the OAR DVHs. The 3D dose 
distribution analysis shows, for pelvic tumors, slight 
differences between planned dose and recalculated 
cumulative dose. For pancreatic carcinoma, local deviations 
up to 30% with respect to the planned dose can be found in 
the daily 3D dose distributions, particularly in healthy tissues 
behind the target volume. 
 
Conclusion: Results confirm that the use of beam directions 
crossing OARs with a high degree of inter-fractional variation, 
as in the abdominal region, should be minimized for actively 
scanned carbon ion beams. However, it is useful to stress 
that results obtained are patient-dependent and more 
statistics is needed to draw a general conclusion for a larger 
population. Research projects are ongoing focused on the 
improvement of in-room 3D imaging techniques and the 
development of dose fast calculation platforms for online 
treatment plans evaluation procedures that account for 
changing anatomy effects. 
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Purpose or Objective: In modern radiotherapy, Cone-Beam 
CT (CBCT) images are widely used for position verification. 
These CBCT images could also be used for dose recalculation, 
providing information for treatment evaluation and adaptive 
planning. However, dose calculations on CBCT are not 
straightforward and the accuracy for clinical cases is not well 
known [1-5]. The final goal was to determine for lung cancer 
patients the accuracy of dose calculations on CBCT images of 
two different vendors: Elekta and Varian. 
 
Material and Methods: Lung cancer patients with CBCT 
imaging (n=10 for Elekta, n=6 for Varian) and a repeated 
planning CT scan on the same day were selected. The original 
treatment plan and delineated structures were copied to the 
repeated CT and CBCT scans, and the dose was recalculated. 
For CBCT dose calculations, an adapted HU-to-electron 
density (HU-ED) table was used which was obtained by 
comparing CT values of corresponding points on the CBCT and 
repeated planning CT scan. For Varian, a bi-annual CBCT HU 
calibration was executed, while for Elekta the absence of 
CBCT HU-calibration was compensated by using a patient-
specific HU-ED table. Planning CT data were used to 
compensate for the limited FOV (Elekta) or scan length 
(Varian) of the CBCT. Finally, clinically relevant dose metrics 
were compared between the repeated CT and CBCT in order 
to assess the accuracy of dose calculations on CBCT for both 
vendors. 
